Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis’s $12 billion takeover of Avidity Biosciences and raises questions about the drugmaker’s growth prospects. Fabienne Kinzel...
Source: [Bloomberg Markets](https://www.bloomberg.com/news/videos/2026-09-08/novartis-sees-avidity-drug-suffer-third-setback-video)